Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aubex Therapeutics
San Diego, California, United Statesaubextherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aubex Therapeutics has launched with a unique R&D program aimed at transforming treatment of solid tumor malignancies by modifying the tumor microenvironment to reduce fibrosis and enhance immune response. Early data show promise particularly in fibrotic cancers such as HER2+ and triple-negative breast cancers, pancreatic, esophageal SCC, colon, and NSCLC. The approach represents an innovative immuno-oncology strategy focusing on TME remodeling to improve patient outcomes.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule novel compounds targeting tumor microenvironment (TME) fibrosis and immune modulation in solid tumors
- Industry
- Biotech
Beyond the preview
Go deeper on Aubex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aubex Therapeutics.